Binding of Resveratrol to Vascular Endothelial Growth Factor Suppresses Angiogenesis by Inhibiting the Receptor Signaling
- 10 December 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 67 (4) , 1127-1137
Abstract
Resveratrol is a polyphenol commonly found in plants and food health products, such as grape and red wine, and was identified for its binding to vascular endothelial growth factor (VEGF) by using HerboChips screening. The binding, therefore, resulted in alterations of VEGF binding to its receptor and revealed the roles of VEGF in angiogenesis. Several lines of evidence gave support to the inhibitory activities of resveratrol in VEGF-triggered angiogenesis. In human umbilical vein endothelial cells (HUVECs), compared with a VEGF-induced group, resveratrol, at a high concentration, suppressed VEGF-mediated endothelial cell proliferation, cell migration, cell invasion, and tube formation by 80 ± 9.01%, 140 ± 3.78%, 110 ± 7.51%, and 120 ± 10.26%, respectively. Moreover, resveratrol inhibited the subintestinal vessel formation in zebrafish embryo. In signaling cascades, application of resveratrol in HUVECs reduced the VEGF-triggered VEGF receptor 2 phosphorylation and c-Jun N-terminal kinase phosphorylation. Moreover, the VEGF-mediated phosphorylations of endothelial nitric oxide synthase, protein kinase B, and extracellular signal-regulated kinase were obviously decreased by (3 ± 0.37)-, (2 ± 0.27)- and (6 ± 0.23)-fold, respectively, in the presence of resveratrol at high concentration. Parallelly, the VEGF-induced reactive oxygen species formation was significantly decreased by 50 ± 7.88% to 120 ± 14.82% under resveratrol treatment. Thus, our results provided support to the antiangiogenic roles of resveratrol, as well as its related signaling mechanisms, in attenuating the VEGF-mediated responses. The present results supported possible development of resveratrol, which should be considered as a therapeutic agent in terms of prevention and clinical treatment of diseases related to angiogenesis.Keywords
Funding Information
- Research Grants Council, University Grants Committee (T13-607/12R)
- China Postdoctoral Science Foundation (2016M600681)
- Shenzhen Science and Technology Committee Research Grant (JCYJ20160229210027564, JCYJ20170326, JCYJ20170413173747440, CKFW2016082916015476, ZDSYS201707281432317, JCYJ20160229205726699, JCYJ20160229205812004)
- HSBC Trustee (Hong Kong) Limited (TUYF15SC01)
- Innovation Technology Fund (UIM/302, UIT/137, UIM/340, ITS/022/16FP)
- Lau Wah Sham Fund (PD18SC01)
This publication has 40 references indexed in Scilit:
- Angiogenesis: update 2005Journal of Thrombosis and Haemostasis, 2005
- Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesisCytokine & Growth Factor Reviews, 2005
- Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissuesArchives of Oral Biology, 2003
- Placental Growth Factor (PlGF) and Its Receptor Flt‐1 (VEGFR‐1)Annals of the New York Academy of Sciences, 2002
- Vascular-specific growth factors and blood vessel formationNature, 2000
- Molecular angiogenesisChemistry & Biology, 1999
- Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinaseFEBS Letters, 1997
- Clinical Applications of Research on AngiogenesisNew England Journal of Medicine, 1995
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Platelet-derived endothelial cell growth factorProgress in Growth Factor Research, 1991